U.S. market Open. Closes in 3 hours 38 minutes

OVID | Ovid Therapeutics Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for OVID we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is exceptionally good and Health is passable.

Valuation (22%)

Company Industry
P/E Ratio (TTM) -2.84 -16.37
PEG Ratio (TTM) 2.07 -1.38
P/S Ratio (TTM) 148.81 49.72
P/B Ratio (TTM) 0.95 20.91
P/FCF Ratio (TTM) -1.59 9.28
Price to 5YR AVG Earnings Ratio -2.34 -0.34
Price to 5YR AVG FCF Ratio -4.83 -7.03

Profitability (0%)

Company Industry
ROA (TTM) -25.19% -3.32%
ROE (TTM) -33.40% 23.64%
Net Profit Margin (TTM) -5,241.52% -1,148.82%
ROIC 5YR AVG -112.88% 16.14%

Growth (88%)

4QTR AVG 3YR AVG 5YR AVG
EPS 41.73% 88.68% 24.73%
Revenue 23.49% 517.19% 275.67%
Net Income 42.42% 67.31% 11.65%
Cash Flow -7.47% 105.61% 37.48%

Health (58%)

Company Industry
Current Ratio (TTM) 5.73 5.82
Quick Ratio (TTM) 5.73 5.53
D/E Ratio (TTM) 0.03 -15.30
Interest Coverage (TTM) -0.04 3.35
Piotroski F-Score 1 5
Altman Z-Score 41.18 13.52
LTL to 5YR AVG FCF -1.72 0.20
Shares Outstanding Growth 5YR AVG 25.66% 120.44%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙